X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2053) 2053
male (1111) 1111
waldenstrom macroglobulinemia - diagnosis (930) 930
aged (918) 918
middle aged (896) 896
female (877) 877
index medicus (728) 728
hematology (541) 541
waldenstrom macroglobulinemia - complications (497) 497
adult (449) 449
diagnosis, differential (446) 446
oncology (395) 395
waldenstrom macroglobulinemia (389) 389
waldenstrom macroglobulinemia - pathology (383) 383
waldenstrom macroglobulinemia - drug therapy (327) 327
aged, 80 and over (284) 284
waldenstrom macroglobulinemia - immunology (254) 254
waldenstroms macroglobulinemia (240) 240
multiple myeloma - diagnosis (224) 224
rituximab (218) 218
prognosis (214) 214
waldenstrom macroglobulinemia - therapy (212) 212
waldenstrom macroglobulinemia - blood (200) 200
diagnosis (198) 198
lymphoma (194) 194
immunoelectrophoresis (180) 180
multiple-myeloma (180) 180
lymphomas (178) 178
waldenstrom macroglobulinemia - genetics (178) 178
waldenstrom's macroglobulinemia (177) 177
multiple myeloma (176) 176
macroglobulinemia (174) 174
treatment outcome (169) 169
chronic lymphocytic-leukemia (163) 163
bone marrow - pathology (144) 144
lymphoplasmacytic lymphoma (141) 141
mutation (141) 141
immunoglobulin m - blood (140) 140
monoclonal gammopathy (140) 140
waldenström macroglobulinemia (140) 140
immunoglobulin m (138) 138
immunoglobulin m - analysis (134) 134
biopsy (128) 128
pathology (127) 127
waldenström's macroglobulinemia (126) 126
medicine, general & internal (123) 123
antineoplastic combined chemotherapy protocols - therapeutic use (122) 122
antineoplastic agents - therapeutic use (121) 121
blood protein electrophoresis (114) 114
retrospective studies (111) 111
therapy (104) 104
immunoglobulins (99) 99
cancer (95) 95
medicine & public health (92) 92
myeloid differentiation factor 88 - genetics (89) 89
consensus panel recommendations (88) 88
leukemia (88) 88
bone marrow (87) 87
waldenstrom macroglobulinemia - mortality (87) 87
chemotherapy (86) 86
disease (86) 86
hematology, oncology and palliative medicine (86) 86
paraproteinemias - diagnosis (86) 86
risk factors (85) 85
igm monoclonal gammopathy (84) 84
multiple myeloma - immunology (83) 83
2nd international workshop (81) 81
abridged index medicus (81) 81
disease progression (81) 81
follow-up studies (81) 81
undetermined significance (80) 80
care and treatment (76) 76
clinical neurology (76) 76
multiple myeloma - complications (75) 75
survival (75) 75
immunophenotyping (73) 73
blood viscosity (71) 71
myd88 l265p (71) 71
patients (71) 71
waldenstrom macroglobulinemia - metabolism (69) 69
amyloidosis (67) 67
multiple myeloma - blood (65) 65
b-cell lymphoma (64) 64
blood protein disorders - diagnosis (64) 64
bortezomib (64) 64
immunoglobulin g - analysis (64) 64
waldenstrom macroglobulinemia - etiology (64) 64
l265p somatic mutation (63) 63
myd88 (62) 62
survival analysis (62) 62
flow cytometry (60) 60
features (59) 59
international workshop (59) 59
multiple myeloma - pathology (59) 59
myeloma (59) 59
immunohistochemistry (58) 58
medical laboratory technology (58) 58
animals (56) 56
fludarabine (56) 56
hemic and lymphatic diseases (56) 56
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1793) 1793
French (178) 178
German (124) 124
Japanese (73) 73
Spanish (55) 55
Italian (39) 39
Russian (27) 27
Chinese (20) 20
Polish (16) 16
Czech (14) 14
Portuguese (12) 12
Dutch (7) 7
Danish (6) 6
Hungarian (6) 6
Romanian (6) 6
Norwegian (4) 4
Croatian (2) 2
Swedish (2) 2
Bulgarian (1) 1
Finnish (1) 1
Hebrew (1) 1
Korean (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Mayo Clinic Proceedings, ISSN 0025-6196, 2010, Volume 85, Issue 9, pp. 824 - 833
Journal Article
Journal Article
Journal Article
Blood, ISSN 0006-4971, 08/2015, Volume 126, Issue 6, pp. 721 - 732
Waldenstrom macroglobulinemia (WM) is a B-cell neoplasm manifested by the accumulation of clonal immunoglobulin (Ig... 
CONSENSUS PANEL RECOMMENDATIONS | 2ND INTERNATIONAL WORKSHOP | L265P SOMATIC MUTATION | MULTIPLE-MYELOMA | RITUXIMAB THERAPY | IMMUNOGLOBULIN-M | MYD88 L265P | LYMPHOPROLIFERATIVE DISORDERS | LYMPHOPLASMACYTIC CELLS | INHIBITOR EVEROLIMUS | HEMATOLOGY | Cyclophosphamide - administration & dosage | Nitrogen Mustard Compounds - administration & dosage | Waldenstrom Macroglobulinemia - therapy | Humans | Middle Aged | Pyrazines - administration & dosage | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Transplantation, Autologous | Molecular Targeted Therapy | Waldenstrom Macroglobulinemia - pathology | Adult | Receptors, CXCR4 - genetics | B-Lymphocytes - pathology | Boronic Acids - administration & dosage | Everolimus | B-Lymphocytes - metabolism | Waldenstrom Macroglobulinemia - diagnosis | Immunoglobulin M - genetics | Gene Expression | Genetic Predisposition to Disease | Sirolimus - analogs & derivatives | Bortezomib | Pyrimidines - administration & dosage | Myeloid Differentiation Factor 88 - genetics | Antineoplastic Combined Chemotherapy Protocols | Hematopoietic Stem Cell Transplantation | Rituximab | Vidarabine - analogs & derivatives | Cladribine - administration & dosage | Plasmapheresis | Receptors, CXCR4 - metabolism | B-Lymphocytes - drug effects | Sirolimus - administration & dosage | Pyrazoles - administration & dosage | Bendamustine Hydrochloride | Aged | Oligopeptides - administration & dosage | Vidarabine - administration & dosage | Myeloid Differentiation Factor 88 - metabolism | Waldenstrom Macroglobulinemia - genetics
Journal Article
Leukemia, ISSN 1476-5551, 2013, Volume 27, Issue 8, pp. 1722 - 1728
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2005, Volume 23, Issue 7, pp. 1564 - 1577
Purpose To review the diagnostic criteria, prognostic factors, response criteria, and treatment options of patients with Waldenstrom's macroglobulinemia (WM... 
CONSENSUS PANEL RECOMMENDATIONS | 2ND INTERNATIONAL WORKSHOP | MULTIPLE-MYELOMA | INTERFERON-ALPHA | ANTI-CD20 MONOCLONAL-ANTIBODY | PROGNOSTIC-FACTORS | ONCOLOGY | RITUXIMAB THERAPY | PHASE-II | CELL TRANSPLANTATION | COOPERATIVE-ONCOLOGY-GROUP | Antibodies, Monoclonal, Murine-Derived | Prognosis